TrialBlood2024

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.

Jennifer R Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.